EQS-News: Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 (english)

Press/Media

Period24 Jan 2024

Media coverage

1

Media coverage

  • TitleEQS-News: Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 (english)
    Media name/outletdpa-AFX International ProFeed
    Country/TerritoryGermany
    Date24/01/24
    PersonsMarla Dubinsky
View all 1
View less